Put Spread on MYL on 8/29/2016

Mylan N.V. (MYL) develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide.

The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream, or ointment forms, as well as active pharmaceutical ingredients (APIs). It is also involved in the development of APIs with non-infringing processes for internal use and to partner with manufacturers; and manufacture and sale of injectable products in antineoplastics, anti-infectives, anesthesia/pain management, and cardiovascular therapeutic areas.

In addition, the company produces finished dosage form and oral solid dose products; and offers antiretroviral therapies to third parties. Further, it manufactures and sells branded specialty injectable and nebulized products comprising EpiPen Auto-Injector to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures.

It sells generic pharmaceutical products to proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies; and specialty pharmaceuticals to pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions.

Shares have formed a bearish "flag" after the company raised prices on its EpiPen. The price hike was coincided with the company granting bonuses to its top executives. The move has seen negative reaction from the public. Several members of the Congress has asked FDA to approve a generic version of EpiPen. This controversy is not over and should continue to push share prices lower. 

We will be trading September 16th Options.

52-Weeks Trading Range: $37.59 - $55.51

Last Trade: $43.03

Trade Buy 1 September $44.00 Put at $1.95 Sell 1 September $40.00 Put at $0.50 For a net debit of $1.45 Profit/Loss Analysis Breakeven at $42.55 Maximum profit is $255.00 at strike of $40.00 Maximum loss is ($145.00) at strike of $44.00 Closing Summary Sold 1 September $44.00 Put at $4.10 Bought 1 September $40.00 Put at $1.20

Position closed on 9/2/2016 at price of $2.90 with a 100.00% gain in 4 days.

Updates

9/2/2016 1:08:01 PM

We are taking profits on MYL Put Spread.

Back to Portfolio